Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and…

By T. Green, K. Young, C. Visco, Z. Xu-Monette, A. Orazi, R. Go, O. Nielsen, O. Gadeberg, T. Mourits‐Andersen, Mikael Frederiksen and 2 more. Journal of Clinical Oncology, 2012

702 citations recorded by the source corpus.

Subfields: Dermatology, Neurology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/9e5eb5a8070999746b1361139f2bd0da1cc6ac09

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Shimin Hu
2. H. Tilly
3. Z. Xu-Monette
4. M. G. Silva
5. A. Tzankov
6. G. Slack
7. U. Vitolo
8. Lin Wu

Citations in the corpus

• Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012, background): “The immunohistochemical expression of MYC and/or BCL2 or both (double expressors) is only partly correlated with genetic abnormalities, but the concurrent expression of MYC and BCL2 is usually associated with a poor outcome [17–19].”
• MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. (2013, methodology): “Approximately one-third of DLBCL demonstrate MYC/BCL2 co-expression, in keeping with the 29% frequency reported in an earlier study by Green et al.23 By contrast, MYC/BCL2 double-hit B-cell lymphoma characterized chromosomal breaks involving MYC and BCL2 is a rare disease, representing approximately”